DRUG EFFICACY;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LIVER TOXICITY;
LYMPHOCYTE COUNT;
NOTE;
SUPERINFECTION;
ANTIVIRAL AGENTS;
DRUG THERAPY, COMBINATION;
HEPATITIS B;
HEPATITIS C;
HIV INFECTIONS;
HUMANS;
Triple infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus: A clinical challenge
Sterling RK. Triple infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus: a clinical challenge. Am J Gastroenterol. 2003;98: 2130-2134.
Tri-infection: Successful treatment of a patient infected with HIV and hepatitis B and C viruses - A case report
Johanson F. Tri-infection: successful treatment of a patient infected with HIV and hepatitis B and C viruses - a case report. AIDS Reader. 2004;14:389-394.
Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B
Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123:1812-1822.
Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients
Liu CJ, Chen PJ, Lai MY, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568-576.
High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial
Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001;96:2973-2977.
Peginterferon alfa-2a (40KD) (PEGASYS) monotherapy is more effective than lamivudine monotherapy in the treatment of HBeAg-negative chronic hepatitis B: 72-Week results from a phase III, partially double-blind study of Pegasys alone vs Pegasys plus lamivudine vs lamivudine
Abstract 95
Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a (40KD) (PEGASYS) monotherapy is more effective than lamivudine monotherapy in the treatment of HBeAg-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of Pegasys alone vs Pegasys plus lamivudine vs lamivudine. J Hepatol. 2004;40(suppl 1):34. Abstract 95.